

LEUKOCARE completes formation of second tier of management

Dr Konstantin Petropoulos hired as new Vice President Business Development, Marketing & Sales to strengthen LEUKOCARE's expansion in becoming the leading provider in the field of proprietary formulation technologies.

Munich, Germany, 25 July 2018

Munich-based biotechnology company LEUKOCARE has announced today the appointment of Dr Konstantin Petropoulos as new Vice President BD, Marketing & Sales.

Dr Konstantin Petropoulos joins LEUKOCARE from Bayer AG, where he was heading Portfolio Operations & Analytics within Bayer's New Product Commercialization & Portfolio Strategy department. Prior to Bayer, he served in various positions at MorphoSys AG. In his last role he was heading the Pre-Commercial Group to support MorphoSys in becoming a fully integrated biopharmaceutical company. Before, he served several years in Business Development focusing on both technology platform and clinical stage compound in- and out-licensing. Dr Petropoulos is a biologist & chemist by training; he holds a PhD and a MBA.

Michael Scholl, CEO at LEUKOCARE, said, "We are very pleased that Dr Petropoulos is joining LEUKOCARE to head our BD, Marketing & Sales team. Based on his strong background and expertise in the field of biopharmaceuticals, business development and strategic marketing he will help achieving the goal of becoming the leading provider in the field of proprietary formulation technologies."

"I am excited and very much looking forward to supporting LEUKOCARE's development and the further rollout of its technologies and services into the pharma and biotech industry," stated Dr Petropoulos. "I am convinced that LEUKOCARE is outstandingly well positioned and that its SPS[®] formulation technology platform provides significant competitive advantages by improving stability of new entities, especially in the growing segments of biologics and viral vector related therapies such as CAR-T or gene therapies as well as life cycle products and biosimilars; thereby creating value to our customers and similarly enabling better solutions for patients in a multitude of indications with unmet medical need."

About LEUKOCARE AG

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow the development of better products. The proprietary Stabilizing and Protecting Solutions (SPS[®]) technologies are provided to development projects of partners in the pharmaceutical and medical device industry. LEUKOCARE's SPS[®] technologies improve stability and quality of biologics like antibodies, vaccines etc. in dry and liquid formulation including high-concentration formulations. SPS[®] technologies also protect proteins in biologically functionalized combination devices.

www.leukocare.com

Contact:

Michael Scholl

michael.scholl@leukocare.com

+49 (0) 89 7801 6650